Navigation Links
U.S. Patent Office Issues Notice of Allowance for Patent Application Related to CTI's GlycoPolymer Technology
Date:11/20/2011

SEATTLE, Nov. 21, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application directed to increasing the plasma half-life of therapeutic proteins and peptides by recombinantly conjugating them to a novel, non-immunogenic peptide repeat sequence. The patent and its related technology are exclusively licensed to Aequus Biopharma, Inc. (Aequus), a majority owned subsidiary of CTI, for the purpose of development and commercialization. The patent application entitled "Conjugates of biologically active proteins having a modified in vivo half-life" has also been filed in other regions and countries, including Europe and Japan. Corresponding patents have been granted in New Zealand, South Africa and Singapore.  

"This U.S. Patent Allowance is an important milestone for Aequus and its development of the GlycoPolymer technology," said Stewart D. Chipman, Ph.D., President and CSO of Aequus. "We believe that this technology has the potential to significantly streamline the development of first-in-class therapeutic proteins and peptides, as well as extend the half-life of existing therapeutic proteins and peptides to improve their therapeutic profile through less frequent dosing, resulting in improved patient compliance. Our lead program, AQB-101, is a novel glycoprotein with G-CSF-like activity that demonstrates an extended plasma half-life.  Aequus is currently generating in vivo data to demonstrate AQB-101's utility, and we look forward to further development of AQB-101 and the GlycoPolymer technology," Dr. Chipman concluded.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

About Aequus BioPharma, Inc.

Headquartered on Bainbridge Island, WA, Aequus BioPharma is a biopharmaceutical company committed to streamlining the development of biopharmaceuticals with improved pharmacokinetic properties in a wide variety of human disease indications. Aequus Biopharma is a majority owned subsidiary of Cell Therapeutics. For additional information, please visit www.aequusbiopharma.com.

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of GlycoPolymer technology include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with  the GlycoPolymer technology in particular including, without limitation, the potential failure to prove safe and effective, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: deramian@ctiseattle.com
www.CellTherapeutics.com/press_room

Investors Contact:

Ed Bell
T: 206.282.7100
Lindsey Jesch Logan
T: 206.272.4347
F: 206.272.4434
E: invest@ctiseattle.com
www.CellTherapeutics.com/investors


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ampio Pharmaceuticals Expands Patent Portfolio of Drugs for Treating Inflammatory Diseases
2. MedBox Develops Patent-Pending System for Storage and Retrieval of Prescription Drugs
3. RSB Spine, LLC, Announces European Patent Allowance
4. Awarepoint Advances Industry Leadership with New Patented Technology
5. Watson Confirms Exelon(R) Patent Challenge
6. Uroplasty Announces Issuance of New Apparatus Patent for the Urgent® PC Neuromodulation System Stimulator
7. Intellect Neurosciences Obtains Two New Patents in Japan for Its Alzheimers Immunotherapy Programs
8. Intellect Neurosciences Responds to Official Action by United States Patent and Trademark Office in Relation to its ANTISENILIN® Alzheimers Patent Application
9. Perrigo Confirms Filing for Testosterone Gel 1.0% and Announcement of Patent Infringement Lawsuit by Abbott
10. Regulus Therapeutics Expands Worldwide Patent Coverage on microRNA-122 to Treat Hepatitis C Virus (HCV) Infection
11. Life Spine Awarded Seven New Patents, Launches Six New Product Lines & Realizes 25% Sales Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2017)... AROMAS, Calif. , Aug. 2, 2017 /PRNewswire/ ... by Continental Who,s Who as a Pinnacle Lifetime ... currently the Key Account Manager at Turing Pharmaceuticals, ... communications, negotiations, troubleshooting and relationship building.                ... has more than 25 years of experience ...
(Date:7/31/2017)... FLINT, Mich. , July 31, 2017  Diplomat Pharmacy, ... companies in southeast Michigan by ... feature ranks private and public companies by three-year revenue growth. ... To view the complete list, ... Crain,s Fast 50 is an incredible triumph," said Phil ...
(Date:7/27/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported ... The Company reported second quarter net sales of $1.954 ... period, and an increase of 2.1% on a constant ... from the LDR Holding Corporation acquisition, second quarter 2017 ... or 0.3% on a constant currency basis. ...
Breaking Medicine Technology:
(Date:8/17/2017)... , ... August 17, 2017 , ... Inc. Magazine Unveils ... at No. 132 with Three-Year Sales Growth of 3,004.8% , NEW YORK, August 16, ... Inc. 5000, the most prestigious ranking of the nation's fastest-growing private companies. The list ...
(Date:8/17/2017)... , ... August 17, 2017 , ... ... Employers , an international competition, were announced today. The awards recognize the world’s ... suppliers who help to create and drive great places to work. , A ...
(Date:8/16/2017)... ... August 16, 2017 , ... Blue Health Intelligence (BHI) ... President, Chief Medical Officer. Dr. Spiro brings over 30 years of clinical, healthcare IT, ... for BHI’s cutting-edge analytics solutions. , “I am thrilled to welcome Dr. Spiro ...
(Date:8/16/2017)... Atlanta, GA (PRWEB) , ... August 16, 2017 , ... ... the new Inc. 5000. The company ranked #4429 on the newly released, 36th annual ... The list represents a unique look at the most successful companies within the American ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... their recently launched community enrichment program. Partnering once again with Boys & Girls ... competition to help find the area’s very own American Idol. With all proceeds ...
Breaking Medicine News(10 mins):